IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 176-200 out of 1241.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

Public Release: 2-Dec-2014
RSNA 2014 100th Scientific Assembly and Annual Meeting
3-D mammography improves cancer detection in dense breasts
A major new study has found that digital breast tomosynthesis, also known as 3-D mammography, has the potential to significantly increase the cancer detection rate in mammography screening of women with dense breasts.

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America

Public Release: 1-Dec-2014
Nature Medicine
Scientists discover why bowel cancer sometimes outsmarts treatment
A new study that challenges the prevailing view of how bowel cancer develops in the large intestine is published today in Nature Medicine.
Cancer Research UK

Contact: Stephanie McClellan
stephanie.mcclellan@cancer.org.uk
44-020-346-95314
Cancer Research UK

Public Release: 1-Dec-2014
Clinical Cancer Research
Breast cancer vaccine shows promise in small clinical trial
A breast cancer vaccine developed at Washington University School of Medicine in St. Louis is safe in patients with metastatic breast cancer, results of an early clinical trial indicate. Preliminary evidence also suggests that the vaccine primed the patients' immune systems to attack tumor cells and helped slow the cancer's progression.
US Department of Defense, Gateway for Cancer Research, Foundation for Barnes-Jewish Hospital

Contact: Diane Duke Williams
williamsdia@wustl.edu
314-286-0111
Washington University School of Medicine

Public Release: 1-Dec-2014
Cancer Research
HIV drug blocks bone metastases in prostate cancer
The receptor CCR5, targeted by HIV drugs, is also key in driving prostate cancer metastases, suggesting that blocking this molecule could slow prostate cancer spread.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 1-Dec-2014
British Journal of Psychiatry
Mental health inequalities in detection of breast cancer
Women with a mental illness are less likely to be screened for breast cancer, according to University of Leicester psychiatrist.

Contact: Dr Alex J Mitchell
ajm80@le.ac.uk
University of Leicester

Public Release: 1-Dec-2014
Proceedings of the National Academy of Sciences
Researchers identify chemical compound that decreases effects of multiple sclerosis
Multiple sclerosis is triggered when the immune system attacks the myelin sheath, the protective covering around the axons of nerve fibers. Currently available therapies are only partially effective in preventing the onset of permanent disability in MS patients. A research team led by the University of California, Riverside has identified a compound that minimizes axon degeneration, reducing the rate and degree of MS progression. This chemical stimulates axon re-sheathing, restoring uninterrupted flow of nerve impulses.
National Multiple Sclerosis Society, National Institutes of Health

Contact: Iqbal Pittalwala
iqbal@ucr.edu
951-827-6050
University of California - Riverside

Public Release: 1-Dec-2014
Genes & Development
Protein kinase R and dsRNAs, new regulators of mammalian cell division
The research team of the Center for RNA Research at IBS has succeeded in revealing that the dsRNAs and Protein Kinase R regulate division of mammalian cells.
Institute for Basic Science

Contact: Hanbin Oh
ohanvin@ibs.re.kr
82-428-788-182
Institute for Basic Science

Public Release: 1-Dec-2014
Oncogene
Stressed-out cancers may provide drug target
Research at the University of Adelaide has discovered cancer cells may be particularly susceptible to metabolic stress -- opening the way for new targeted therapy that won't harm normal cells.
National Health and Medical Research Council

Contact: Stephen Gregory
stephen.gregory@adelaide.edu.au
61-466-987-583
University of Adelaide

Public Release: 1-Dec-2014
American Journal of Pathology
Prognostic role found for miR-21 expression in triple-negative breast cancer
'Triple-negative' breast cancer occurs in patients whose cells do not express receptors for estrogen, progesterone, and/or human epidermal growth factor receptor 2 (ER/PR/HER2). Because of the absence of these predictive biomarkers, treatment assignment can be difficult. Now, researchers report that high levels of the microRNA miR-21 in the tumor microenvironment, but not in the tumor epithelia, are associated with worse clinical outcomes for patients with triple-negative breast cancer, thus identifying a possible triple-negative breast cancer prognostic biomarker.
NIH/National Cancer Institute, NIH/National Center for Research Resources, Van Andel Research Institute, Hitchcock Foundation, Van Andel Institute Purple Community

Contact: Eileen Leahy
ajpmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 1-Dec-2014
Proceedings of the National Academy of Sciences
Widely used osteoporosis drugs may prevent breast, lung and colon cancers
The most commonly used medications for osteoporosis worldwide, bisphosphonates, may also prevent certain kinds of lung, breast and colon cancers.
National Institutes of Health, Italian Space Agency, National Science Foundation of China, National Center for Advancing Translational Science/Mount Sinai School of Medicine's Clinical and Translational Science Award

Contact: Renatt Brodsky
renatt.brodsky@mountsinai.org
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 1-Dec-2014
Journal of Clinical Oncology
Triple-negative breast cancer patients should undergo genetic screening: Mayo Clinic
Most patients with triple-negative breast cancer should undergo genetic testing for mutations in known breast cancer predisposition genes, including BRCA1 and BRCA2, a Mayo Clinic-led study has found. The findings come from the largest analysis to date of genetic mutations in this aggressive form of breast cancer. The results of the research appear in the Journal of Clinical Oncology.
National Institutes of Health, Breast Cancer Research Foundation, David F. and Margaret T. Grohne Family Foundation

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic

Public Release: 28-Nov-2014
Leukemia
New substance overcomes treatment-restistance in leukemia
Haematologists from Goethe University Frankfurt, working with a Russian pharmaceutical company, have developed a new active substance that effectively combats the most aggressive forms of Philadelphia chromosome-positive leukemia.

Contact: Martin Ruthardt
ruthardt@em.uni-frankfurt.de
Goethe University Frankfurt

Public Release: 27-Nov-2014
Science
A numbers game: Math helps to predict how the body fights disease
Walter and Eliza Hall Institute researchers have defined for the first time how the size of the immune response is controlled, using mathematical models to predict how powerfully immune cells respond to infection and disease.
National Health and Medical Research Council, Human Frontier Science Program, Australian Research Council, Science Foundation Ireland, Australian Postgraduate Award scheme,Edith Moffatt Scholarship Fund, Victorian Government

Contact: Vanessa Solomon
solomon@wehi.edu.au
61-393-452-971
Walter and Eliza Hall Institute

Public Release: 27-Nov-2014
JAMA Otolaryngology - Head & Neck Surgery
Survival differences seen for advanced-stage laryngeal cancer
The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy, or removal of the voice box, to treat the disease, despite a national trend toward organ preservation, according to a report published online by JAMA Otolaryngology-Head & Neck Surgery.

Contact: Sally Croom
scroom@lsuhsc.edu
318-675-8769
The JAMA Network Journals

Public Release: 26-Nov-2014
Nature
Study finds potential predictive biomarker for response to PD-L1 checkpoint blocker
Scientists analyzed tissue samples from patients who had -- and had not -- responded to a promising new immunotherapy drug. The study could help identify patients most likely to respond to the new drug, which blocks PD-L1.
Genentech Inc.

Contact: Teresa M Herbert
teresa_herbert@dfci.harvard.edu
617-632-5653
Dana-Farber Cancer Institute

Public Release: 26-Nov-2014
56th American Society of Hematology Annual Meeting
New England Journal of Medicine
Two studies identify a detectable, pre-cancerous state in the blood
Researchers from the Broad Institute, Harvard Medical School, and Harvard-affiliated hospitals have uncovered an easily detectable, 'pre-malignant' state in the blood that significantly increases the likelihood that an individual will go on to develop blood cancers such as leukemia, lymphoma, or myelodysplastic syndrome. The discovery, which was made independently by two research teams affiliated with the Broad and partner institutions, opens new avenues for research aimed at early detection and prevention of blood cancer.
National Institutes of Health, Gabrielle's Angel Foundation, Leukemia and Lymphoma Society, Stanley Center for Psychiatric Research, NIH/National Human Genome Research Institute, NIH/National Institute of Mental Health, Wellcome Trust, and others

Contact: Veronica Meade-Kelly
veronica@broadinstitute.org
617-714-7113
Broad Institute of MIT and Harvard

Public Release: 26-Nov-2014
ecancermedicalscience
How a common antacid could lead to cheaper anti-cancer drugs
A popular indigestion medication can increase survival in colorectal cancer, according to research published in ecancermedicalscience. But in fact, scientists have studied this for years -- and a group of cancer advocates want to know why this research isn't more widely used. 'Cimetidine is a drug that can meet patient needs now -- so we need to ask ourselves: what's stopping it being used?' asks Pantziarka.

Contact: Katie Foxall
katie@ecancer.org
01-179-420-852
ecancermedicalscience

Public Release: 26-Nov-2014
Cell Reports
Enzyme may be key to cancer progression in many tumors
A new University of Iowa study provided a deeper understanding of how KRAS turns off tumor suppressor genes and identifies a key enzyme in the process. The findings, published online Nov. 26 in the journal Cell Reports, suggest that this enzyme, known as TET1, may be an important target for cancer diagnostics and treatment.
NIH/National Cancer Institute

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-621-5266
University of Iowa Health Care

Public Release: 26-Nov-2014
Nature
Scientists discover treatment breakthrough for advanced bladder cancer
Scientists from Queen Mary University of London have made a major breakthrough in developing a new therapy for advanced bladder cancer -- for which there have been no major treatment advances in the past 30 years.

Contact: Charli Scouller
c.scouller@qmul.ac.uk
020-788-27943
Queen Mary, University of London

Public Release: 26-Nov-2014
Nature
Vaccines may make war on cancer personal
In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality.

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine

Public Release: 26-Nov-2014
Critical Public Health
More public health interventions required to tackle grim reaper of 'lifestyle' diseases
More public health interventions, along the lines of the smoking ban, are needed to tackle Britain's devastating toll of 'lifestyle' diseases, including heart disease and cancer, according to academics.

Contact: Deborah Linton
deborah.linton@manchester.ac.uk
44-016-127-58257
University of Manchester

Public Release: 26-Nov-2014
Nature
Study unlocks basis of key immune protein's two-faced role
A Brigham and Women's Hospital-led team has identified a long sought-after partner for a key immune protein, called TIM-3, that helps explain its two-faced role in the immune system.

Contact: Jessica Caragher
jcaragher@partners.org
617-525-6373
Brigham and Women's Hospital

Public Release: 26-Nov-2014
Nature
SU2C-supported research discovers why patients respond to a life-saving melanoma drug
Reported in Nature online, Dr. Antoni Ribas, co-leader of the CRI-SU2C Immunology Dream Team and colleagues at UCLA Jonsson CCC studied tumor biopsies from 46 advance melanoma patients taken before and after treatment with pembrolizumab (Keytruda), the new FDA-approved breakthrough drug. Using biopsy findings created an algorithm to predict the likelihood whether patients would likely to respond to this treatment.
Stand Up To Cancer, National Institute of Health, UCLA Jonsson Comprehensive Cancer Center

Contact: Jane Rubinstein
jrubinstein@eifoundation.org
516-993-0708
Entertainment Industry Foundation

Public Release: 26-Nov-2014
Oncotarget
Research team proves the efficacy of new drug against stem cells that provoke the growth of cancer
An Andalusian team of researchers led by the University of Granada has designed a drug that fights cancerogenic stem cells responsible for the onset and development of cancer, for relapse after chemotherapy, and for metastasis. The new drug, called Bozepinib, has been successfully tested in mice, and has a selective action against cancerogenic stem cells for breast and colon cancer, as well as melanoma.

Contact: Juan Antonio Marchal Corrales
jmarchal@ugr.es
0034-958-249-321
University of Granada

Public Release: 26-Nov-2014
RSNA 2014 100th Scientific Assembly and Annual Meeting
Trial shows new imaging system may cut X-ray exposure for liver cancer patients
Johns Hopkins researchers report that their test of an interventional X-ray guidance device approved by the US Food and Drug Administration in 2013 has the potential to reduce the radiation exposure of patients undergoing intra-arterial therapy for liver cancer.
Max Kade Foundation, NIH/National Cancer Institute, Philips Research North America

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Showing releases 176-200 out of 1241.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>